



(51) International Patent Classification:

A61P 17/00 (2006.01) C07K 16/28 (2006.01)
A61P 37/02 (2006.01)

(21) International Application Number:

PCT/US2024/052505

(22) International Filing Date:

23 October 2024 (23.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/592,351 23 October 2023 (23.10.2023) US
63/642,002 03 May 2024 (03.05.2024) US

(71) Applicant: **ABCELLERA BIOLOGICS INC.** [CA/CA];
2215 Yukon Street, Vancouver, British Columbia V5Y 0A1
(CA).

(72) Inventor; and

(71) Applicant: **GOODMAN, Allison** [US/CA]; 2215 Yukon
Street, Vancouver, British Columbia V5Y 0A1 (CA).

(72) Inventors: **WILLIAMSON, Christopher**; 2215 Yukon
Street, Vancouver, British Columbia V5Y 0A1 (CA).
MACDONALD, Madeline; 2215 Yukon Street, Vancou-

ver, British Columbia V5Y 0A1 (CA). **KUANG, Tal-**
lie; 2215 Yukon Street, Vancouver, British Columbia
V5Y 0A1 (CA). **YAMNIUK, Aaron Paul**; 2215 Yukon
Street, Vancouver, British Columbia V5Y 0A1 (CA).
LAMEIGNERE, Emilie; 2215 Yukon Street, Vancouver,
British Columbia V5Y 0A1 (CA). **DUNCAN, Sherie**; 2215
Yukon Street, Vancouver, British Columbia V5Y 0A1 (CA).
BARNHART, Bryan Crawford; 2215 Yukon Street, Van-
couver, British Columbia V5Y 0A1 (CA). **AMASH, Alaa**;
2215 Yukon Street, Vancouver, British Columbia V5Y 0A1
(CA). **NIEMIETZ, Iwona**; 2215 Yukon Street, Vancouver,
British Columbia V5Y 0A1 (CA).

(74) Agent: **CAWLEY, Thomas A., Jr.** et al.; Potomac Law
Group, PLLC, 1717 Pennsylvania Ave, NW, Ste 1025,
Washington, District of Columbia 20006 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: ANTI-OX40L ANTIBODIES AND METHODS OF USE



FIGURE 1A




FIGURE 1B




FIGURE 1C

(57) Abstract: Anti-OX40L antibodies and methods of using the same for detecting, preventing and/or treating various autoimmune disorders or Atopic Dermatitis.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*